All Updates

All Updates

icon
Filter
Product updates
Verséa Discovery launches mescreen Research Validator for mitochondrial compound assessment
Precision Medicine
Aug 27, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Aug 27, 2024

Verséa Discovery launches mescreen Research Validator for mitochondrial compound assessment

Product updates

  • Verséa Discovery has launched its novel research tool, mescreen Research Validator, designed to collect crucial data on mitochondrial function, assisting in developing, formulating, and clinically validating various health-related products.

  • mescreen leverages patented bioassay, imaging, and ML methods to provide insights into mitochondrial efficiency and the clinical impacts of different test substances. The platform is claimed to have assisted research by analyzing over 60 FDA-approved compounds and agents known to affect mitochondrial function. The company is developing a mescreen-personalized mitochondrial efficiency test to offer individuals a detailed energy profile for enhancing their overall well-being.

  • Verséa Discovery specializes in developing cutting-edge research platforms and personalized medicine solutions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.